CANbridge Pharmaceuticals Inc. (HKG:1228)
Hong Kong · Delayed Price · Currency is HKD 1.990
0.00 (0.00%)
Jul 31, 2026, 4:08 PM HKT
CANbridge Pharmaceuticals Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 66.63 | 10.5 | 137.49 | 463.11 | 745.82 |
Cash & Short-Term Investments | 66.63 | 10.5 | 137.49 | 463.11 | 745.82 |
Cash Growth | 534.40% | -92.36% | -70.31% | -37.91% | 106.71% |
Accounts Receivable | 15.12 | 16.72 | 31.23 | 19.05 | 9.14 |
Other Receivables | 7.47 | 9.87 | 8.29 | - | 18.76 |
Receivables | 22.58 | 26.59 | 39.52 | 19.05 | 27.9 |
Inventory | 20.57 | 7.9 | 8.78 | 9.82 | 13.45 |
Other Current Assets | 0.39 | 0.36 | 24.08 | 13.18 | 24.54 |
Total Current Assets | 110.17 | 45.35 | 209.86 | 505.16 | 811.71 |
Property, Plant & Equipment | 0.51 | 3.64 | 109.01 | 144.72 | 29.54 |
Other Intangible Assets | 54.71 | 67.82 | 76.49 | 49.01 | 51.27 |
Other Long-Term Assets | - | - | - | 3.16 | - |
Total Assets | 165.39 | 116.81 | 395.36 | 702.05 | 892.52 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 368.83 | 370.46 | 198.05 | 107.54 | 43.61 |
Accrued Expenses | 60.76 | 68.7 | 63.46 | 114.98 | 93.82 |
Current Portion of Long-Term Debt | 7.03 | 15.33 | 23.69 | 26.87 | 30.87 |
Current Portion of Leases | 0.91 | 11.76 | 11.03 | 13.03 | 7.88 |
Current Unearned Revenue | 2.73 | - | - | - | - |
Other Current Liabilities | 15.08 | 16.37 | 31.71 | 15.69 | 9.6 |
Total Current Liabilities | 455.34 | 482.61 | 327.95 | 278.11 | 185.78 |
Long-Term Debt | 8 | 15.04 | 6.63 | 10.78 | - |
Long-Term Leases | 0.14 | 93.65 | 100.58 | 104.61 | 13.35 |
Long-Term Unearned Revenue | 43.66 | - | - | - | - |
Total Liabilities | 507.15 | 591.3 | 435.15 | 393.49 | 199.13 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Additional Paid-In Capital | 3,588 | 3,474 | 3,473 | 3,471 | 3,471 |
Retained Earnings | -4,189 | -4,210 | -3,789 | -3,411 | -2,927 |
Comprehensive Income & Other | 259.01 | 261.79 | 276.55 | 247.88 | 149.89 |
Shareholders' Equity | -341.76 | -474.49 | -39.79 | 308.56 | 693.39 |
Total Liabilities & Equity | 165.39 | 116.81 | 395.36 | 702.05 | 892.52 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 16.08 | 135.78 | 141.93 | 155.28 | 52.1 |
Net Cash (Debt) | 50.54 | -125.28 | -4.44 | 307.83 | 693.71 |
Net Cash Growth | - | - | - | -55.63% | - |
Net Cash Per Share | 0.11 | -0.29 | -0.01 | 0.73 | 7.36 |
Filing Date Shares Outstanding | 511.12 | 424.56 | 424.56 | 424.29 | 424.19 |
Total Common Shares Outstanding | 511.12 | 424.56 | 424.56 | 424.29 | 424.19 |
Working Capital | -345.17 | -437.26 | -118.08 | 227.06 | 625.93 |
Book Value Per Share | -0.67 | -1.12 | -0.09 | 0.73 | 1.63 |
Tangible Book Value | -396.47 | -542.31 | -116.28 | 259.54 | 642.12 |
Tangible Book Value Per Share | -0.78 | -1.28 | -0.27 | 0.61 | 1.51 |
Machinery | 9.46 | 10.68 | 16.58 | 13.54 | 4.79 |
Leasehold Improvements | 1.94 | 1.94 | 3.94 | 10.86 | 11.32 |